Company Description:
Building Products & Materials Firm
Building Products & Materials Firm
Construction Executive Online
Construction Job Openings
Company News
- J&J’s Spravato momentum points to commercial viability of psychedelics for mental health, analysts say - Proactive financial news (news.google.com)
- Rocket boosts preparations for gene therapy launch with new commercial chief from J&J, AstraZeneca - Fierce Pharma (news.google.com)
- Business brief | Sibanye gets wind win; US court rejects R184bn J&J baby powder settlement - News24 (news.google.com)
- J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production - BioSpace (news.google.com)
- Robert C. Johnson III Elected to Board of Directors for Johnson & Johnson - Insurance Journal (news.google.com)
- Eric Davidson Joins Mendaera’s Executive Ranks as Chief Commercial Officer - Medical Product Outsourcing (news.google.com)
- Ryan Jenkins Named Executive Director for Business Development at J&J Worldwide Services - GovCon Wire (news.google.com)
- J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold - Fierce Pharma (news.google.com)
- J&J's ketamine-derived nasal spray approved by FDA to treat depression - Fox Business (news.google.com)
- J&J pauses US rollout of Varipulse heart device after stroke reports - The Straits Times (news.google.com)
- Mendaera hires chief commercial officer for handheld medical robot launch - Fierce Pharma (news.google.com)
- J&J Tire to celebrate 40 years in business - The Desert Review (news.google.com)
- Johnson & Johnson awards its US and Canada media business to WPP - Ad Age (news.google.com)
- J&J’s Tremfya TV ad calls out psoriasis diagnosis gap for patients of color - Campaign US (news.google.com)
- Johnson & Johnson reports first commercial Varipulse use in Canada - MassDevice (news.google.com)
- Johnson & Johnson sets 'new standard in inclusive marketing' with diverse Tremfya psoriasis ad - Fierce Pharma (news.google.com)
- J&J subsidiary files for bankruptcy again to settle talc lawsuits - Fox Business (news.google.com)
- Ins & Outs: J&J, BioMarin, and Telix announce leadership changes - BioProcess International (news.google.com)
- J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition - Yahoo Finance (news.google.com)
- Legend continues Carvykti factory builds to cement CAR-T territory with J&J - Endpoints News (news.google.com)
- Touting Shockwave’s Billion-Dollar Potential, J&J Lifts 2024 Guidance - BioSpace (news.google.com)
- Johnson & Johnson brings in billions from remaining Kenvue stake - MassDevice (news.google.com)
- Lykos shores up commercial team for MDMA drug; Former J&J CEO Alex Gorsky finds his next gig - Endpoints News (news.google.com)
- J&J boosts heart device business in $13.1 bln Shockwave deal - Reuters (news.google.com)
- J&J, Legend expand manufacturing deal with Novartis to include commercial production of Carvykti - Fierce Pharma (news.google.com)
- J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer - statnews.com (news.google.com)
- J&J to shut Peninsula facility it opened less than 2 years ago but open another - The Business Journals (news.google.com)
- J&J Worldwide Services to be Acquired by CBRE Group - WashingtonExec (news.google.com)
- World's Largest Real Estate Brokerage's $1 Billion Deal Pushes Business Toward Government Work - CoStar (news.google.com)
- CBRE Group, Inc. Expands Public Sector Capabilities with Agreement to Acquire J&J Worldwide Services - Business Wire (news.google.com)
- J&J’s Spravato success confirms commercial viability of psychedelics for mental health - Proactive financial news (news.google.com)
- Spurred by Abiomed deal, J&J medtech business grows in 2023 - The Business Journals (news.google.com)
- FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe - Fierce Pharma (news.google.com)
- J&J leader spotlights neglected needs in maternal health - drugdiscoverytrends.com (news.google.com)
- J&J bets bigger on MeiraGTx’s eye gene therapy - BioPharma Dive (news.google.com)
- Vanda expands commercial presence with $100M deal for US rights to J&J multiple sclerosis drug - Fierce Pharma (news.google.com)
- UPDATED: As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth - Fierce Pharma (news.google.com)
- Lafayette Parish Schools backed out of deal to buy part of the old Walmart. Now they're being sued. - The Advocate (news.google.com)
- How Johnson & Johnson is Accelerating a Health Equity Mindset: the Business Match Fund - NationSwell (news.google.com)
- J&J to restructure orthopedic business after medical device sales miss - Reuters (news.google.com)
- J&J to restructure orthopedics business - MedTech Dive (news.google.com)
- J&J MedTech is restructuring its DePuy Synthes orthopedics business - MassDevice (news.google.com)
- J&J begins restructuring at medical device unit after sales miss - The Business Times (news.google.com)
- Johnson & Johnson unloads eye drops line to acquisitive Bausch + Lomb as Brent Saunders' deal streak rolls on - Fierce Pharma (news.google.com)
- Johnson & Johnson cites rebates and discounts for drug price increases - Fierce Pharma (news.google.com)
- J&J, Legend tap Novartis to help make CAR-T drug Carvykti as they work through supply constraints - Fierce Pharma (news.google.com)
- J&J Carpet closes after 50 years of business in Lexington - the-dispatch.com (news.google.com)
- Dexcom appoints former J&J exec as CCO, sets 2023 guidance - MassDevice (news.google.com)
- J&J completes $16.6B acquisition of local medical device firm - The Business Journals (news.google.com)
- Johnson & Johnson buys Danvers medical device firm Abiomed for $16.6 billion - The Boston Globe (news.google.com)
- J&J to buy heart pump maker Abiomed for $16.6 bln ahead of consumer health spinoff - Reuters (news.google.com)
- J&J Expands Cardiovascular Business with $16.6B Abiomed Acquisition - BioSpace (news.google.com)
- J&J names consumer health business Kenvue ahead of spin-off - Reuters (news.google.com)
- J&J kicks off prostate cancer health disparities campaign with pro football Hall-of-Famer Shannon Sharpe - Fierce Pharma (news.google.com)
- Explained: What is the controversy around J&J's talc-based baby powder? - Business Standard (news.google.com)
- J&J to end global sales of talc-based baby powder - Inquirer.net (news.google.com)
- Johnson & Johnson to replace talc-based powder with cornstarch - BBC (news.google.com)
- Johnson & Johnson Drops Talcum Powder Globally as Lawsuits Mount - Bloomberg.com (news.google.com)
- Commercial CAR-Ts: Ensuring lentivirus supply key for J&J and BMS - BioProcess International (news.google.com)
- J&J, Roche partner Halozyme buys Antares Pharma for $1B, beefing up drug delivery offerings - Fierce Pharma (news.google.com)
- J&J expands it long-acting injectables partnership with Midatech - Drug Delivery Business (news.google.com)
- With J&J-partnered CAR-T nod in hand, Legend CEO eyes earlier myeloma use, cheaper cell therapy manufacturing - Fierce Pharma (news.google.com)
- Johnson & Johnson, Legend's CAR-T Carvykti enters myeloma ring with FDA nod - Fierce Pharma (news.google.com)
- Baby Powder to Band-Aid: Key facts on J&J's consumer health business - Reuters (news.google.com)
- J&J to spin off consumer products and focus on pharmaceuticals - Reuters (news.google.com)
- J&J Vision Care’s Limerick plant is key to global mission - Business Post (news.google.com)
- Countries Are Sitting on Millions of J&J Vaccine Doses, Report Says - Business Insider (news.google.com)
- Robert C. Johnson III, Johnson & Johnson - Insurance Business America (news.google.com)
- Johnson & Johnson targets different audiences with Xarelto TV commercial trio - Fierce Pharma (news.google.com)
- Johnson & Johnson to buy surgical robotics firm Auris for $3.4 billion - Reuters (news.google.com)
- Janssen Immunology — Science & Market Drivers - Life Science Leader (news.google.com)
- Bob Shaw's Engineered Floors to merge with J&J Industries - Chattanooga Times Free Press (news.google.com)
- Fortified OTC play to keep J&J healthy - Business Standard (news.google.com)